abstract |
The present invention relates to a pharmaceutical composition comprising fingolimod, a pharmaceutically acceptable salt thereof or a phosphate derivative, having less than about 0.5% concentration (w/w) of Impurity I after six months stability study at 40°C and 75% RH. |